A Phase I, Single-Arm, Open Label, Dose Escalation, Multicenter Study of Off-the-Shelf Natural Killer (NK) Cells (SAR445419) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

被引：1
|
作者：
Konopleva, Marina Y. [1 ,2 ]
Bhatt, Vijaya Raj [3 ]
Mantzaris, Ioannis [4 ]
Maiti, Abhishek [5 ]
Gundabolu, Krishna [3 ]
Jensen, Kyle [6 ]
Schafer, Jolie [6 ]
Mi, Gu [6 ]
Drewniak, Agata [6 ]
Krenz, Heidi [6 ]
Saleem, Rao [6 ]
Abbadessa, Giovanni [6 ]
Daver, Naval [5 ]
机构：
[1] Montefiore Med Ctr, Dept Oncol, 111 E 210Th St, Bronx, NY 10467 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Univ Nebraska, Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA
[4] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[6] Sanofi, Cambridge, MA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174030
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] A Phase 2, Single-Arm, Multicohort, Open Label, Multicenter Trial of Off-the-Shelf Natural Killer Cells (SAR445419) in Patients with High-Risk Myeloid Malignancies Undergoing Allogeneic HSCT
    Al Malki, Monzr M.
    Solh, Melhem M.
    Singh, Anurag K.
    Patel, Rushang D.
    Roy, Denis-Claude
    Drewniak, Agata
    Mi, Gu
    Tracey, Lorraine
    Abbadessa, Giovanni
    Champlin, Richard E.
    BLOOD, 2023, 142
  • [2] RESULTS OF A PHASE 2, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY OF LENALIDOMIDE IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
    O'Brien, Maureen
    Alonzo, Todd
    Cooper, Todd
    Levine, John
    Brown, Patrick
    Slone, Tamra
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Quan, Jackie
    Simcock, Mathew
    Weiss, Daniel
    Zimmerman, Linda
    Kolb, Edward
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [3] Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia
    O'Brien, Maureen M.
    Alonzo, Todd A.
    Cooper, Todd M.
    Levine, John E.
    Brown, Patrick A.
    Slone, Tamra
    August, Keith J.
    Benettaib, Bouchra
    Biserna, Noha
    Poon, Jennifer
    Patturajan, Meera
    Chen, Nianhang
    Simcock, Mathew
    Zimmerman, Linda
    Kolb, E. Anders
    PEDIATRIC BLOOD & CANCER, 2021, 68 (07)
  • [4] A Phase 1 Study of WU-NK-101 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
    Cashen, Amanda F.
    Liu, Hongtao
    Al Malki, Monzr M.
    Zeidner, Joshua F.
    Foster, Matthew C.
    Pannunzio, Angela
    Ramsey, Brett
    Baughman, Jan
    Muth, John
    Bakkacha, Ouiam
    McNulty, Eileen
    Jacobs, Kenneth
    Davidson-Moncada, Jan K.
    Wei, Andrew H.
    BLOOD, 2022, 140 : 12740 - 12741
  • [5] Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia
    Boyiadzis, Michael
    Agha, Mounzer
    Redner, Robert L.
    Sehgal, Alison
    Im, Annie
    Hou, Jing-Zhou
    Farah, Rafic
    Dorritie, Kathleen A.
    Raptis, Anastasios
    Lim, Seah H.
    Wang, Hong
    Lapteva, Natalia
    Mei, Zhuyong
    Butterfield, Lisa H.
    Rooney, Cliona M.
    Whiteside, Theresa L.
    CYTOTHERAPY, 2017, 19 (10) : 1225 - 1232
  • [6] Phase 1 Clinical Trial of Adoptive Immunotherapy Using "Off-the-Shelf" Activated Natural Killer Cells (aNK) in Patients with Refractory/Relapsed Acute Myeloid Leukemia
    Boyiadzis, Michael
    Agha, Mounzer
    Redner, Robert L.
    Sehgal, Alison
    Im, Annie
    Hou, Jing-Zhou
    Farah, Rafic
    Dorritie, Kathleen A.
    Raptis, Anastasios
    Lim, Seah H.
    Klingemann, Hans
    Wang, Hong
    Lapteva, Natalia
    Mei Zhuyong
    Butterfield, Lisa H.
    Rooney, Cliona M.
    Whiteside, Theresa L.
    BLOOD, 2016, 128 (22)
  • [7] Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.
    Stein, Eytan M.
    Dinardo, Courtney Denton
    Pollyea, Daniel Aaron
    Fathi, Amir Tahmasb
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    Flinn, Ian
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Stein, Anthony Selwyn
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Knight, Robert D.
    Agresta, Samuel V.
    De Botton, Stephane
    Tallman, Martin S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Confirmatory open-label, single-arm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
    Topp, Max S.
    Goekbuget, Nicola
    Stein, Anthony Selwyn
    Bargou, Ralf C.
    Dombret, Herve
    Fielding, Adele K.
    Ribera, Josep M.
    Foa, Robin
    Zugmaier, Gerhard
    Holland, Chris
    Maniar, Tapan
    Huber, Birgit
    Nagorsen, Dirk
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study
    Huang, Hui-qiang
    Kim, Won-Seog
    Yao, Ming
    Kim, Tae Min
    Yoon, DocHyun
    Cho, Seok-Goo
    Eom, Hyeon-Seok
    Yeh, Su-Peng
    Lim, Soon Thye
    Song, Yuqin
    Liu, Shizhou
    Gao, Grace
    Zhang, Lijia
    Qing, Min
    Qi, Ming
    Kim, Jin Seok
    Kwong, Yok Lam
    Jin, Jie
    Shi, Yuankai
    Zhu, Jun
    BLOOD, 2019, 134
  • [10] Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH)
    Liu, Chuanxu
    Gao, Yan
    Yu, Yang
    Guo, Zhi
    Zhao, Jun
    Tao, Rong
    Huang, Huiqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345